Mitsubishi UFJ Asset Management UK Ltd. Acquires Shares of 2,000 Thermo Fisher Scientific Inc. $TMO

Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 2,000 shares of the medical research company’s stock, valued at approximately $1,159,000.

Several other large investors have also bought and sold shares of TMO. High Note Wealth LLC grew its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the period. Beacon Financial Strategies CORP bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth $29,000. HFM Investment Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 341.7% in the 4th quarter. HFM Investment Advisors LLC now owns 53 shares of the medical research company’s stock worth $31,000 after purchasing an additional 41 shares during the last quarter. Finally, JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This trade represents a 3.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on TMO shares. TD Cowen reduced their price target on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Barclays reduced their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Citigroup raised their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $616.10.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $448.34 on Wednesday. The business’s 50-day moving average price is $483.39 and its two-hundred day moving average price is $540.37. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market cap of $166.61 billion, a PE ratio of 24.65, a P/E/G ratio of 1.96 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.